{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dextrose&page=59",
    "query": {
      "intervention": "dextrose",
      "page": 59
    },
    "page_size": 10
  },
  "pagination": {
    "page": 59,
    "page_size": 10,
    "total_count": 3591,
    "total_pages": 360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dextrose&page=60&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dextrose&page=58&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T09:07:42.368Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04665739",
      "title": "Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lung Neuroendocrine Tumor",
        "Functioning Lung Neuroendocrine Tumor",
        "Locally Advanced Lung Neuroendocrine Neoplasm",
        "Lung Neuroendocrine Neoplasm",
        "Lung Neuroendocrine Tumor G1",
        "Lung Neuroendocrine Tumor G2",
        "Metastatic Lung Neuroendocrine Neoplasm",
        "Metastatic Lung Neuroendocrine Tumor",
        "Non-Functioning Lung Neuroendocrine Tumor",
        "Recurrent Lung Neuroendocrine Neoplasm",
        "Unresectable Lung Neuroendocrine Neoplasm",
        "Unresectable Lung Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Lutetium Lu 177 Dotatate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Single Photon Emission Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2023-02-03",
      "completion_date": "2032-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-28T09:07:42.368Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04665739"
    },
    {
      "nct_id": "NCT06143202",
      "title": "Feasibility of CGM Use in Hospitalized Youth",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Freestyle Libre 3 Continuous Glucose Monitor",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "2 Years to 26 Years"
      },
      "enrollment_count": 120,
      "start_date": "2025-07-15",
      "completion_date": "2027-02-14",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-10-28T09:07:42.368Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Stanford, California • Aurora, Colorado",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06143202"
    },
    {
      "nct_id": "NCT00542009",
      "title": "A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Weight Management",
        "Treatment Of Obesity"
      ],
      "interventions": [
        {
          "name": "CE-326,597 100 mg QD",
          "type": "DRUG"
        },
        {
          "name": "CE-326,597 50 mg QD",
          "type": "DRUG"
        },
        {
          "name": "CE-326,597 25 mg QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "CE-326,597 5mg QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 252,
      "start_date": "2007-12",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2012-11-07",
      "last_synced_at": "2026-10-28T09:07:42.368Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Fresno, California • National City, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00542009"
    },
    {
      "nct_id": "NCT06336798",
      "title": "Bioenergetic Effect of Pioglitazone in CLD-PH",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Hypertension",
        "Pulmonary Hypertension Due to Lung Diseases"
      ],
      "interventions": [
        {
          "name": "Pioglitazone 30mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Labs",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-12-17",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-28T09:07:42.368Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06336798"
    },
    {
      "nct_id": "NCT01405300",
      "title": "The Effects of Peanuts and Peanut Products on Glucose Control and Vascular Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Control",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Peanut",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Penn State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "20 Years to 50 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2011-08",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-10-28T09:07:42.368Z",
      "location_count": 1,
      "location_summary": "University Park, Pennsylvania",
      "locations": [
        {
          "city": "University Park",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01405300"
    },
    {
      "nct_id": "NCT07444671",
      "title": "Impact of Time-restricted Eating on Sleep, Glucose and Insulin Sensitivity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Time Restricted Eating"
      ],
      "interventions": [
        {
          "name": "Time restricted eating",
          "type": "OTHER"
        },
        {
          "name": "Control eating",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Colorado State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2018-12-07",
      "completion_date": "2021-05-25",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-10-28T09:07:42.368Z",
      "location_count": 1,
      "location_summary": "Fort Collins, Colorado",
      "locations": [
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07444671"
    },
    {
      "nct_id": "NCT01185171",
      "title": "Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "ZD 1839 500mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2003-01-27",
      "completion_date": "2018-08",
      "has_results": true,
      "last_update_posted_date": "2023-05-11",
      "last_synced_at": "2026-10-28T09:07:42.368Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01185171"
    },
    {
      "nct_id": "NCT07449039",
      "title": "Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gestational Diabetes Mellitus in Pregnancy"
      ],
      "interventions": [
        {
          "name": "Continuous Glucose Monistor",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2025-09-28",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-10-28T09:07:42.368Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07449039"
    },
    {
      "nct_id": "NCT03991299",
      "title": "Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Obese",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Botox 200 UNT Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2021-04-29",
      "completion_date": "2022-02-11",
      "has_results": true,
      "last_update_posted_date": "2023-02-28",
      "last_synced_at": "2026-10-28T09:07:42.368Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03991299"
    },
    {
      "nct_id": "NCT03765164",
      "title": "Glucose Control Using 1,5-AG Testing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "GlycoMark 1-5-AG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Clinical Performance and Value Vignettes",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Qure Healthcare, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 156,
      "start_date": "2018-11-05",
      "completion_date": "2019-02-24",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-10-28T09:07:42.368Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03765164"
    }
  ]
}